Bioada is a next-generation biotechnology company revolutionizing early disease detection and treatment through AI-powered multi-omics. Our proprietary platform is the only solution globally capable of analyzing all omics data types—genomics, transcriptomics, proteomics, metabolomics, and beyond—while solving the long-standing biomarker reproducibility problem. From a single gene in the blood, Bioada has discovered highly accurate liquid biopsy biomarkers for early detection of breast, pancreatic, and Alzheimer’s diseases, all with >95% sensitivity and specificity. Our diagnostics pipeline also includes first-of-its-kind biomarkers for Parkinson’s disease and Facioscapulohumeral muscular dystrophy (FSHD). On the therapeutics front, we’ve identified novel driver genes and therapeutic targets across multiple diseases including glioblastoma, multiple sclerosis, and lung cancer. Our platform, Genomarker, integrates advanced machine learning with structured biological knowledge, enabling unprecedented insight into complex diseases—even from technically challenging single-cell data. Founded with the belief that speed and precision in biomedical discovery can coexist, Bioada operates at the intersection of AI, omics, and clinical relevance. We are headquartered in Canada with global collaborations spanning research institutions, patient foundations, and biopharma. Bioada’s mission is to bring powerful, affordable, and actionable diagnostics and therapeutics to patients everywhere—faster than ever before.